Literature DB >> 24385341

Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.

Henri M H Spronk1, Anne Margreet de Jong, Harry J Crijns, Ulrich Schotten, Isabelle C Van Gelder, Hugo Ten Cate.   

Abstract

Factor Xa and thrombin are well-known components of the coagulation cascade and have been proven to be viable targets for effective anticoagulation treatment. However, accumulating evidence suggests that these serine proteases are also crucial modulators of other cellular mechanisms through the activation of protease-activated receptor (PAR)-mediated signalling. The involvement of factor Xa, thrombin, and PARs in normal biological and pathophysiological processes has been recognized, and their potential implications have been explored in recent years. Both factor Xa and thrombin play significant roles in mediating cellular signalling effects associated with the initial development of atherosclerosis: a chronic inflammatory vascular disease. In addition, increased expression and activation of PARs may be associated with atrial fibrillation (AF) and AF-associated thromboembolism hypercoagulability. Both pathologies are associated with hypercoagulability, suggesting that the role of cellular effects of factor Xa and thrombin and of their specific inhibitors should be studied in relation to the prevention of thrombotic and pro-arrhythmic changes. This review examines the role of factor Xa-mediated and thrombin-mediated PAR activation in modulating cellular processes involved in atherosclerosis and AF and discusses the potential implication of direct factor Xa and thrombin inhibition on effects outside coagulation.

Entities:  

Keywords:  Anticoagulants; Atherosclerosis; Receptors; Thrombin

Mesh:

Substances:

Year:  2014        PMID: 24385341     DOI: 10.1093/cvr/cvt343

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  28 in total

1.  Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation.

Authors:  Hiromasa Katoh; Tsuyoshi Nozue; Ichiro Michishita
Journal:  Heart Vessels       Date:  2017-03-10       Impact factor: 2.037

Review 2.  DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm.

Authors:  Feng Gao; Faisal Rahman
Journal:  Curr Atheroscler Rep       Date:  2022-04-07       Impact factor: 5.113

3.  Coagulation factors promote brown adipose tissue dysfunction and abnormal systemic metabolism in obesity.

Authors:  Yuka Hayashi; Ippei Shimizu; Yohko Yoshida; Ryutaro Ikegami; Masayoshi Suda; Goro Katsuumi; Shinya Fujiki; Kazuyuki Ozaki; Manabu Abe; Kenji Sakimura; Shujiro Okuda; Toshiya Hayano; Kazuhiro Nakamura; Kenneth Walsh; Naja Zenius Jespersen; Søren Nielsen; Camilla Scheele; Tohru Minamino
Journal:  iScience       Date:  2022-06-07

Review 4.  Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.

Authors:  Anke C Fender; Reza Wakili; Dobromir Dobrev
Journal:  Pharmacol Res       Date:  2019-05-02       Impact factor: 7.658

5.  Antiplatelet Therapy Following Peripheral Arterial Interventions: The Choice Is Yours.

Authors:  Aaron W Aday; J Antonio Gutierrez
Journal:  Circ Cardiovasc Interv       Date:  2020-08-14       Impact factor: 6.546

6.  Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.

Authors:  Kanjana S Perera; Kelvin K H Ng; Sumiti Nayar; Luciana Catanese; Leanne Dyal; Mukul Sharma; Stuart J Connolly; Salim Yusuf; Jackie Bosch; John W Eikelboom; Robert G Hart
Journal:  JAMA Neurol       Date:  2020-01-01       Impact factor: 18.302

7.  Arrhythmia Recurrence After Atrial Fibrillation Ablation: Impact of Warfarin vs. Non-Vitamin K Antagonist Oral Anticoagulants.

Authors:  Songnan Wen; Cristina Pislaru; Kristi H Monahan; Stephanie M Barnes; David O Hodge; Douglas L Packer; Sorin V Pislaru; Samuel J Asirvatham
Journal:  Cardiovasc Drugs Ther       Date:  2021-05-18       Impact factor: 3.947

8.  Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia.

Authors:  Sergi Torramade-Moix; Marta Palomo; Manel Vera; Didac Jerez; Ana Belen Moreno-Castaño; M Urooj Zafar; Jordi Rovira; Fritz Diekmann; Joan Carles Garcia-Pagan; Gines Escolar; Aleix Cases; Maribel Diaz-Ricart
Journal:  Cardiovasc Drugs Ther       Date:  2021-06       Impact factor: 3.727

9.  Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice.

Authors:  Nobuhiro Nakanishi; Koichi Kaikita; Masanobu Ishii; Yu Oimatsu; Tatsuro Mitsuse; Miwa Ito; Kenshi Yamanaga; Koichiro Fujisue; Hisanori Kanazawa; Daisuke Sueta; Seiji Takashio; Yuichiro Arima; Satoshi Araki; Taishi Nakamura; Kenji Sakamoto; Satoru Suzuki; Eiichiro Yamamoto; Hirofumi Soejima; Kenichi Tsujita
Journal:  Circ Rep       Date:  2020-03-04

10.  Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.

Authors:  Gilles R Dagenais; Leanne Dyal; Jacqueline J Bosch; Darryl P Leong; Victor Aboyans; Scott D Berkowitz; Deepak L Bhatt; Stuart J Connolly; Keith A A Fox; Eva Muehlhofer; Jeffrey L Probstfield; Petr Widimsky; Bernhard R Winkelmann; Salim Yusuf; John W Eikelboom
Journal:  Heart       Date:  2021-05-21       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.